Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.430 +0.030 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,780,151
Open 3.400
Bid (Size) 3.450 (18,000)
Ask (Size) 3.500 (5,000)
Prev. Close 3.400
Today's Range 3.390 - 3.630
52wk Range 0.6925 - 4.175
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-7.5%
-7.5%
1 Month
+3.9%
+3.9%
3 Month
+15.9%
+15.9%
6 Month
+65.7%
+65.7%
1 Year
+82.4%
+82.4%

More News

Read More
News headline image
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗
Via Stocktwits
News headline image
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
Via Chartmill
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase ↗
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
What is the current price of Esperion Therapeutics, Inc. - Common Stock?
The current price of Esperion Therapeutics, Inc. - Common Stock is 3.430
When was Esperion Therapeutics, Inc. - Common Stock last traded?
The last trade of Esperion Therapeutics, Inc. - Common Stock was at 02/13/26 04:00 PM ET
What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 96.99M
How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
Esperion Therapeutics, Inc. - Common Stock has 97M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.